The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2017 | The open questions surrounding immunotherapy and targeted therapy in lung cancer
Solange Peters, MD, PhD from the University of Lausanne, Lausanne, Switzerland discusses some of the open questions that surround targeted therapy and immunotherapy in patients with lung cancer. The major question that is currently being discussed is whether immunotherapy should be given to patients where there is a significantly reduced response and, whether certain therapies should be given to never-smokers. This interview was recorded at the annual meeting of European Lung Cancer Conference (ELCC) 20171 in Geneva, Switzerland.
